GENELUX-Final-Logo-Notagline.png
Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
September 21, 2022 08:06 ET | Genelux Corporation
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy Trial will be conducted as a collaboration between Genelux and The...
Genelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions
July 28, 2016 08:00 ET | Genelux Corporation
First two patients dosed in Phase 1b Trial in Ovarian Cancer at Florida Hospital Cancer Institute (FHCI) First three patients dosed in Phase 1b Trial in Solid Organ Cancers at Moores Cancer Center at...
Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma
May 27, 2015 08:00 ET | Genelux Corporation
Data Demonstrate Favorable Safety Profile and Anti-Tumor Activity Results to be Presented at ASCO Annual Meeting 2015 During Two Poster Presentations SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) --...
Genelux to Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 at ASCO Annual Meeting 2015
May 12, 2015 08:00 ET | Genelux Corporation
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced...